Strategic Product Launch: Revenue Generation : Peptide Pen line adds new product category to CELLGENIC's portfolio, distributed through RMTG's global network spanning 30+ countries Market Positioning : Pre-loaded synergistic formulations address growing demand for convenient peptide therapy solutions in regenerative and longevity medicine Distribution Advantage : Exclusive sales to licensed physicians through established RMTG affiliate network, including recent Brazil, Dominican Republic, and northern Argentina/Paraguay partnerships Summit Launch Platform : Global Summit presentation generated immediate physician interest and orders from international attendees representing 30+ countries Product Line Expansion : Peptide Pens complement existing CELLGENIC portfolio including exosomes, MSCs, and platelet-rich plasma kits, increasing average order value Educational Integration : ISSCA training programs incorporate peptide therapy protocols, driving product adoption through certification workshops and physician education "We are thrilled with GSCG's launch of CELLGENIC's innovative Peptide Pen product line, which represents a groundbreaking advancement in regenerative medicine," said David Christensen, CEO of RMTG
These percentages are similar to those last year [Figure 12.9]
Rybelsus (Oral Semaglutide) Rybelsus is the first oral GLP-1 receptor agonist, offering an alternative for those who prefer oral medication
Wednesday are FREE days here at Prime IV in Brentwood
Signs of deficiency include: A simple blood test can confirm your B12 levels and help determine if injections are right for you
